{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:02:29Z","timestamp":1790654549217,"version":"4.1.0"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.neuropharm.2024.109949","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T23:44:15Z","timestamp":1713311055000},"page":"109949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Single administration of a psychedelic [(R)-DOI] influences coping strategies to an escapable social stress"],"prefix":"10.1016","volume":"252","author":[{"given":"Kevin T.","family":"Krupp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6629-0897","authenticated-orcid":false,"given":"Jazmine D.W.","family":"Yaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leighton J.","family":"Ledesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuraj Harishchandra Hikkaduwa","family":"Withanage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9549-4917","authenticated-orcid":false,"given":"J.J.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chase B.","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor J.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Sathyanesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel S.","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9051-2696","authenticated-orcid":false,"given":"Cliff H.","family":"Summers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2024.109949_bib1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/PPA.S29716","article-title":"Treatment-resistant depression: therapeutic trends, challenges, and future directions","volume":"6","author":"Al-Harbi","year":"2012","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.neuropharm.2024.109949_bib2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.beproc.2015.06.011","article-title":"Frozen with fear: conditioned suppression in a virtual reality model of human anxiety","volume":"118","author":"Allcoat","year":"2015","journal-title":"Behav. Process."},{"key":"10.1016\/j.neuropharm.2024.109949_bib3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neubiorev.2013.11.005","article-title":"Biological and psychological markers of stress in humans: focus on the trier social stress test","volume":"38","author":"Allen","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2024.109949_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.0963-7214.2005.00336.x","article-title":"Resilience and vulnerability to daily stressors assessed via diary methods","volume":"14","author":"Almeida","year":"2005","journal-title":"Curr. Dir. Psychol. Sci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0149-7634(01)00064-1","article-title":"Non-human primate models for investigating fear and anxiety","volume":"26","author":"Barros","year":"2002","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2024.109949_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2045-5380-1-9","article-title":"Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression","volume":"1","author":"Belzung","year":"2011","journal-title":"Biol. Mood Anxiety Disord."},{"key":"10.1016\/j.neuropharm.2024.109949_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrn1846","article-title":"New approaches to antidepressant drug discovery: beyond monoamines","volume":"7","author":"Berton","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib8","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1037\/0022-3514.46.4.877","article-title":"Coping, stress, and social resources among adults with unipolar depression","volume":"46","author":"Billings","year":"1984","journal-title":"J. Pers. Soc. Psychol."},{"key":"10.1016\/j.neuropharm.2024.109949_bib9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0031-9384(01)00490-5","article-title":"Social defeat as a stressor in humans","volume":"73","author":"Bjorkqvist","year":"2001","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2024.109949_bib10","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.neubiorev.2013.06.008","article-title":"The role of behavior in translational models for psychopathology: functionality and dysfunctional behaviors","volume":"37","author":"Blanchard","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2024.109949_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0031-9384(01)00449-8","article-title":"Animal models of social stress: effects on behavior and brain neurochemical systems","volume":"73","author":"Blanchard","year":"2001","journal-title":"Physiol. Behav."},{"issue":"7","key":"10.1016\/j.neuropharm.2024.109949_bib12","doi-asserted-by":"crossref","DOI":"10.1021\/acschemneuro.8b00692","article-title":"Chronic, Intermittent Microdoses of the psychedelic N, N-dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents","volume":"10","author":"Cameron","year":"2019","journal-title":"ACS Chem. Neurosci"},{"key":"10.1016\/j.neuropharm.2024.109949_bib13","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1021\/acschemneuro.8b00134","article-title":"Effects of N,N-dimethyltryptamine on rat behaviors relevant to anxiety and depression","volume":"9","author":"Cameron","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2024.109949_bib15","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/dta.1333","article-title":"Head\u2010twitch response in rodents induced by the hallucinogen 2, 5\u2010dimethoxy\u20104\u2010iodoamphetamine: a comprehensive history, a re\u2010evaluation of mechanisms, and its utility as a model","volume":"4","author":"Canal","year":"2012","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neuropharm.2024.109949_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.109949_bib17","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus Escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2024.109949_bib18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.109949_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2022.114258","article-title":"Anxiolytic reversal of classically conditioned\/chronic stress-induced gene expression and learning in the Stress Alternatives Model","volume":"440","author":"Carpenter","year":"2023","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2024.109949_bib20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.nlm.2009.01.009","article-title":"Learning strategies during fear conditioning","volume":"91","author":"Carpenter","year":"2009","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.neuropharm.2024.109949_bib21","first-page":"16","article-title":"Real-world data on SSRI antidepressant side effects","volume":"6","author":"Cascade","year":"2009","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.neuropharm.2024.109949_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00441-013-1606-x","article-title":"Social stress models in depression research: what do they tell us?","volume":"354","author":"Chaouloff","year":"2013","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.neuropharm.2024.109949_bib23","doi-asserted-by":"crossref","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","article-title":"fastp: an ultra-fast all-in-one FASTQ preprocessor","volume":"34","author":"Chen","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.neuropharm.2024.109949_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12868-015-0169-z","article-title":"A pre-conditioning stress accelerates increases in mouse plasma inflammatory cytokines induced by stress","volume":"16","author":"Cheng","year":"2015","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib25","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/neu.20025","article-title":"Chronic stress alters dendritic morphology in rat medial prefrontal cortex","volume":"60","author":"Cook","year":"2004","journal-title":"J. Neurobiol."},{"key":"10.1016\/j.neuropharm.2024.109949_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-10904-8","article-title":"Sphingosine-1-phosphate receptor 3 in the medial prefrontal cortex promotes stress resilience by reducing inflammatory processes","volume":"10","author":"Corbett","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2024.109949_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/gigascience\/giab008","article-title":"Twelve years of SAMtools and BCFtools","volume":"10","author":"Danecek","year":"2021","journal-title":"GigaScience"},{"key":"10.1016\/j.neuropharm.2024.109949_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0091-3057(00)00477-9","article-title":"Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice","volume":"68","author":"Darmani","year":"2001","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2024.109949_bib29","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1176\/appi.ps.201300059","article-title":"A review of the clinical, Economic, and Societal burden of treatment-resistant depression: 1996\u20132013","volume":"65","author":"David","year":"2014","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.neuropharm.2024.109949_bib30","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1523\/JNEUROSCI.1659-20.2020","article-title":"Hallucinogens in mental Health: preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine","volume":"41","author":"De Gregorio","year":"2021","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49913-4","article-title":"Fully automated head-twitch detection system for the study of 5-HT2A receptor pharmacology in vivo","volume":"9","author":"de la Fuente Revenga","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2024.109949_bib32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/2045125316638008","article-title":"Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years","volume":"6","author":"dos Santos","year":"2016","journal-title":"Therapeutic Advances in Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.109949_bib33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2288-2-8","article-title":"Do multiple outcome measures require p-value adjustment?","volume":"2","author":"Feise","year":"2002","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.neuropharm.2024.109949_bib34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0165-0270(80)90012-6","article-title":"The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs","volume":"2","author":"File","year":"1980","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2024.109949_bib35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.neulet.2017.10.058","article-title":"Influence of intertrial interval on basal and drug-induced impulsive action in the 5-choice serial reaction time task: effects of d-amphetamine and (\u00b1)-2, 5-dimethoxy-4-iodoamphetamine","volume":"662","author":"Fitzpatrick","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2024.109949_bib36","first-page":"488","article-title":"Structure\u2013Activity relationship analysis of psychedelics in a rat model of asthma reveals the anti-inflammatory pharmacophore","volume":"2","author":"Flanagan","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci. 4"},{"key":"10.1016\/j.neuropharm.2024.109949_bib37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/09540261.2018.1481827","article-title":"Psychedelics as anti-inflammatory agents","volume":"30","author":"Flanagan","year":"2018","journal-title":"Int. Rev. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.109949_bib38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/7854_2022_367","article-title":"Psychedelics and anti-inflammatory activity in animal models","volume":"56","author":"Flanagan","year":"2022","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.neuropharm.2024.109949_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116790","article-title":"5-HT(2) receptor activation alleviates airway inflammation and structural remodeling in a chronic mouse asthma model","volume":"236","author":"Flanagan","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49987-0","article-title":"Activation of 5-HT(2) receptors reduces inflammation in vascular tissue and cholesterol levels in high-fat diet-fed apolipoprotein E knockout mice","volume":"9","author":"Flanagan","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2024.109949_bib41","first-page":"1517","article-title":"Depression is the leading cause of disability around the world","volume":"317","author":"Friedrich","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2024.109949_bib42","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.drudis.2016.01.016","article-title":"Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity","volume":"21","author":"Gerhard","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neuropharm.2024.109949_bib43","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41593-018-0198-x","article-title":"Parallel circuits from the bed nuclei of stria terminalis to the lateral hypothalamus drive opposing emotional states","volume":"21","author":"Giardino","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib44","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.neuroscience.2009.08.053","article-title":"Structural and functional alterations to rat medial prefrontal cortex following chronic restraint stress and recovery","volume":"164","author":"Goldwater","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2024.109949_bib45","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.neuroimage.2016.08.013","article-title":"Chronic psychosocial stress in mice leads to changes in brain functional connectivity and metabolite levels comparable to human depression","volume":"142","author":"Grandjean","year":"2016","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuropharm.2024.109949_bib46","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2024.109949_bib47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.109949_bib48","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1016\/j.neuropsychologia.2010.09.019","article-title":"No fear no risk! Human risk behavior is affected by chemosensory anxiety signals","volume":"48","author":"Haegler","year":"2010","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.neuropharm.2024.109949_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107933","article-title":"Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species","volume":"167","author":"Halberstadt","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.109949_bib50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuropharm.2018.01.049","article-title":"Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans","volume":"142","author":"Heal","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.109949_bib51","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.expneurol.2011.10.032","article-title":"Current research trends in early life stress and depression: review of human studies on sensitive periods, gene\u2013environment interactions, and epigenetics","volume":"233","author":"Heim","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2024.109949_bib52","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/0269881112466185","article-title":"The failure of the antidepressant drug discovery process is systemic","volume":"27","author":"Hendrie","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2024.109949_bib53","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1021\/acschemneuro.9b00493","article-title":"Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression","volume":"11","author":"Hibicke","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib54","doi-asserted-by":"crossref","first-page":"666.661.","DOI":"10.1096\/fasebj.2019.33.1_supplement.666.1","article-title":"Psychedelics improve the mental Health of rats","volume":"33","author":"Hibicke","year":"2019","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2024.109949_bib55","doi-asserted-by":"crossref","first-page":"16136","DOI":"10.1073\/pnas.1415191111","article-title":"Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress","volume":"111","author":"Hodes","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2024.109949_bib56","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/ilar\/ilu002","article-title":"Social defeat as an animal model for depression","volume":"55","author":"Hollis","year":"2014","journal-title":"ILAR J."},{"key":"10.1016\/j.neuropharm.2024.109949_bib57","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.yhbeh.2006.06.022","article-title":"Social conflict models: can they inform us about human psychopathology?","volume":"50","author":"Huhman","year":"2006","journal-title":"Horm. Behav."},{"key":"10.1016\/j.neuropharm.2024.109949_bib58","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1037\/a0025178","article-title":"Development of a measure of the experience of being bullied in youth","volume":"24","author":"Hunt","year":"2012","journal-title":"Psychol. Assess."},{"key":"10.1016\/j.neuropharm.2024.109949_bib59","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1093\/beheco\/14.3.438","article-title":"A survey of the statistical power of research in behavioral ecology and animal behavior","volume":"14","author":"Jennions","year":"2003","journal-title":"Behav. Ecol."},{"key":"10.1016\/j.neuropharm.2024.109949_bib60","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","article-title":"Potential therapeutic effects of psilocybin","volume":"14","author":"Johnson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2024.109949_bib61","first-page":"143","article-title":"The abuse potential of medical psilocybin according to","volume":"142","author":"Johnson","year":"2018","journal-title":"the 8 factors of the Controlled Substances Act. Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.109949_bib62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nm.2075","article-title":"A key role for orexin in panic anxiety","volume":"16","author":"Johnson","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2024.109949_bib63","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1021\/acsptsci.3c00123","article-title":"Transient elevation of plasma glucocorticoids supports psilocybin-induced anxiolysis in mice","volume":"6","author":"Jones","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib64","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3390\/brainsci9070158","article-title":"The impact of ethologically relevant stressors on adult mammalian neurogenesis","volume":"9","author":"Jorgensen","year":"2019","journal-title":"Brain Sci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fnsys.2016.00069","article-title":"Putting the \u201cbiology\u201d back into \u201cneurobiology\u201d: the strength of diversity in animal model systems for neuroscience research","volume":"10","author":"Keifer","year":"2016","journal-title":"Front. Syst. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib66","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/7854_2009_9","article-title":"Epidemiology of anxiety disorders","volume":"2","author":"Kessler","year":"2010","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.neuropharm.2024.109949_bib67","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype","volume":"37","author":"Kim","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neuropharm.2024.109949_bib68","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/nn.4414","article-title":"Antagonistic negative and positive neurons of the basolateral amygdala","volume":"19","author":"Kim","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib69","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1034\/j.1601-5215.2003.00026.x","article-title":"The role of the cytokine network in psychological stress","volume":"15","author":"Kim","year":"2003","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.neuropharm.2024.109949_bib70","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3109\/10253890.2012.663836","article-title":"Long-term effects of footshock and social defeat on anxiety-like behaviours in rats: relationships to pre-stressor plasma corticosterone concentration","volume":"15","author":"Kinn R\u00f8d","year":"2012","journal-title":"Stress"},{"key":"10.1016\/j.neuropharm.2024.109949_bib71","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1097\/CCM.0b013e31819cefe4","article-title":"Zinc deficiency increases organ damage and mortality in a murine model of polymicrobial sepsis","volume":"37","author":"Knoell","year":"2009","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.neuropharm.2024.109949_bib72","doi-asserted-by":"crossref","first-page":"10544","DOI":"10.1523\/JNEUROSCI.3007-12.2013","article-title":"Activation of serotonin 2A receptors underlies the psilocybin-induced effects on \u03b1 oscillations, N170 visual-evoked potentials, and visual hallucinations","volume":"33","author":"Kometer","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib73","first-page":"69","article-title":"Social stress in rats and mice","volume":"640","author":"Koolhaas","year":"1997","journal-title":"Acta Physiol. Scand. Suppl."},{"key":"10.1016\/j.neuropharm.2024.109949_bib74","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0028-3908(99)00159-8","article-title":"Activation of 5-HT2A receptors impairs response control of rats in a five-choice serial reaction time task","volume":"39","author":"Koskinen","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.109949_bib75","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cell.2007.09.018","article-title":"Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions","volume":"131","author":"Krishnan","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2024.109949_bib76","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/7854_2010_108","article-title":"Animal models of depression: molecular perspectives","volume":"7","author":"Krishnan","year":"2011","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.neuropharm.2024.109949_bib77","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.neuron.2019.02.005","article-title":"Ketamine: a paradigm shift for depression research and treatment","volume":"101","author":"Krystal","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2024.109949_bib78","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.tips.2017.08.003","article-title":"Psychedelic drugs in biomedicine","volume":"38","author":"Kyzar","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib79","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0165-0327(00)00343-8","article-title":"Fear and anxiety: animal models and human cognitive psychophysiology","volume":"61","author":"Lang","year":"2000","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2024.109949_bib80","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.neuropharm.2024.109949_bib81","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0091-3057(94)90422-7","article-title":"Anxiolytic-like effect of paroxetine in a rat social interaction test","volume":"49","author":"Lightowler","year":"1994","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2024.109949_bib82","series-title":"The Top Prescription Drugs of 2011 in the United States: Antipsychotics and Antidepressants once Again Lead CNS Therapeutics","author":"Lindsley","year":"2012"},{"key":"10.1016\/j.neuropharm.2024.109949_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2023.173659","article-title":"Prophylactic effects of arketamine, but not hallucinogenic psychedelic DOI nor non-hallucinogenic psychedelic analog lisuride, in lipopolysaccharide-treated mice and mice exposed to chronic restrain stress","volume":"233","author":"Liu","year":"2023","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2024.109949_bib84","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.brainresbull.2016.05.016","article-title":"Ketamine abuse potential and use disorder","volume":"126","author":"Liu","year":"2016","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2024.109949_bib85","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.neuropharm.2024.109949_bib86","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1038\/s41380-021-01159-1","article-title":"An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress","volume":"26","author":"Lu","year":"2021","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.109949_bib87","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bbr.2006.07.029","article-title":"Effects of unpredictable chronic mild stress on anxiety and depression-like behavior in mice","volume":"175","author":"Mineur","year":"2006","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2024.109949_bib88","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41380-018-0119-0","article-title":"Panic results in unique molecular and network changes in the amygdala that facilitate fear responses","volume":"25","author":"Molosh","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.109949_bib89","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1034\/j.1600-0706.2003.12010.x","article-title":"Arguments for rejecting the sequential Bonferroni in ecological studies","volume":"100","author":"Moran","year":"2003","journal-title":"Oikos"},{"key":"10.1016\/j.neuropharm.2024.109949_bib90","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0005-7967(00)00026-7","article-title":"Protective and vulnerability factors of depression in normal adolescents","volume":"39","author":"Muris","year":"2001","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.neuropharm.2024.109949_bib91","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jad.2019.07.076","article-title":"Classical psychedelics for the treatment of depression and anxiety: a systematic review","volume":"258","author":"Muttoni","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2024.109949_bib92","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.neuropharm.2024.109949_bib93","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/beheco\/arh107","article-title":"A farewell to Bonferroni: the problems of low statistical power and publication bias","volume":"15","author":"Nakagawa","year":"2004","journal-title":"Behav. Ecol."},{"key":"10.1016\/j.neuropharm.2024.109949_bib94","article-title":"Serotonin 5-HT2A receptor activation blocks TNF-\u03b1 mediated inflammation in vivo","volume":"8","author":"Nau Jr","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2024.109949_bib95","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0896-6273(02)00653-0","article-title":"Neurobiology of depression","volume":"34","author":"Nestler","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2024.109949_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109232","article-title":"Psychedelics as potent anti-inflammatory therapeutics","volume":"219","author":"Nichols","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.109949_bib97","doi-asserted-by":"crossref","first-page":"825.823","DOI":"10.1096\/fasebj.31.1_supplement.825.3","article-title":"Psychedelics as A new anti-inflammatory therapeutic for atherosclerosis","volume":"31","author":"Nichols","year":"2017","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2024.109949_bib98","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as medicines: an emerging new paradigm","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin. Pharmacol. Therapeut."},{"key":"10.1016\/j.neuropharm.2024.109949_bib99","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2024.109949_bib100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.forsciint.2018.01.006","article-title":"Is LSD toxic?","volume":"284","author":"Nichols","year":"2018","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.neuropharm.2024.109949_bib101","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41398-017-0083-5","article-title":"Shifting priorities: highly conserved behavioral and brain network adaptations to chronic stress across species","volume":"8","author":"Nikolova","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2024.109949_bib102","doi-asserted-by":"crossref","DOI":"10.1177\/1179069518800508","article-title":"Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics","volume":"12","author":"Olson","year":"2018","journal-title":"J. Exp. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib103","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report","volume":"37","author":"Os\u00f3rio","year":"2015","journal-title":"Brazilian Journal of Psychiatry"},{"key":"10.1016\/j.neuropharm.2024.109949_bib104","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2024.109949_bib105","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/2045125312445469","article-title":"The drugs don't work? antidepressants and the current and future pharmacological management of depression","volume":"2","author":"Penn","year":"2012","journal-title":"Therapeutic Advances in Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.109949_bib106","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1136\/bmj.316.7139.1236","article-title":"What's wrong with Bonferroni adjustments","volume":"316","author":"Perneger","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.neuropharm.2024.109949_bib107","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","article-title":"Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial","volume":"176","author":"Phillips","year":"2019","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.109949_bib108","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.35082","article-title":"Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor","volume":"7","author":"Preller","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.neuropharm.2024.109949_bib109","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/cne.21588","article-title":"Repeated stress alters dendritic spine morphology in the rat medial prefrontal cortex","volume":"507","author":"Radley","year":"2008","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2024.109949_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2004.01.006","article-title":"Chronic behavioral stress induces apical dendritic reorganization in pyramidal neurons of the medial prefrontal cortex","volume":"125","author":"Radley","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2024.109949_bib111","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.it.2005.11.006","article-title":"Cytokines sing the blues: inflammation and the pathogenesis of depression","volume":"27","author":"Raison","year":"2006","journal-title":"Trends Immunol."},{"key":"10.1016\/j.neuropharm.2024.109949_bib112","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1037\/bne0000056","article-title":"Interaction of metabolic stress with chronic mild stress in altering brain cytokines and sucrose preference","volume":"129","author":"Remus","year":"2015","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib113","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.physbeh.2015.03.036","article-title":"Nuance and behavioral cogency: how the visible burrow system inspired the stress-alternatives model and conceptualization of the continuum of anxiety","volume":"146","author":"Robertson","year":"2015","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2024.109949_bib114","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.psychres.2015.10.032","article-title":"Meta-analysis of short-and mid-term efficacy of ketamine in unipolar and bipolar depression","volume":"230","author":"Romeo","year":"2015","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2024.109949_bib115","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.109949_bib116","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2024.109949_bib117","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","article-title":"No adjustments are needed for multiple comparisons","volume":"1","author":"Rothman","year":"1990","journal-title":"Epidemiology"},{"key":"10.1016\/j.neuropharm.2024.109949_bib118","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","volume":"142","author":"Rucker","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.109949_bib119","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study","volume":"36","author":"Sanches","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2024.109949_bib120","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(95)00153-N","article-title":"Regulation of anxiety by GABAA receptors in the rat amygdala","volume":"52","author":"Sanders","year":"1995","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2024.109949_bib121","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/10253890.2017.1298587","article-title":"Restraint stress differentially regulates inflammation and glutamate receptor gene expression in the hippocampus of C57BL\/6 and BALB\/c mice","volume":"20","author":"Sathyanesan","year":"2017","journal-title":"Stress"},{"key":"10.1016\/j.neuropharm.2024.109949_bib122","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1037\/a0035302","article-title":"From stress to inflammation and major depressive disorder: a social signal transduction theory of depression","volume":"140","author":"Slavich","year":"2014","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.neuropharm.2024.109949_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2014.00121","article-title":"Neuropeptide S and BDNF gene expression in the amygdala are influenced by social decision-making under stress","volume":"8","author":"Smith","year":"2014","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib124","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.psyneuen.2015.10.016","article-title":"Intensity of anxiety is modified via complex integrative stress circuitries","volume":"63","author":"Smith","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2024.109949_bib125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00213-002-1252-6","article-title":"Discriminative stimulus properties of 1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane [(\u00b1) DOI] in C57BL\/6J mice","volume":"166","author":"Smith","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.109949_bib126","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev.clinpsy.1.102803.143948","article-title":"The psychobiology of depression and resilience to stress: implications for prevention and treatment","volume":"1","author":"Southwick","year":"2005","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.neuropharm.2024.109949_bib127","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neuropharm.2018.09.016","article-title":"Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression","volume":"143","author":"Staton","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.109949_bib128","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00213-019-05414-w","article-title":"Prospective examination of synthetic 5-methoxy-N, N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment","volume":"237","author":"Uthaug","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.109949_bib129","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1475-6773.2006.00512.x","article-title":"When to combine hypotheses and adjust for multiple tests","volume":"41","author":"Veazie","year":"2006","journal-title":"Health Serv. Res."},{"key":"10.1016\/j.neuropharm.2024.109949_bib130","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib131","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4088\/JCP.13m08852","article-title":"Ketamine safety and tolerability in clinical trials for treatment-resistant depression","volume":"76","author":"Wan","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2024.109949_bib132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00427414","article-title":"The validity of animal models of depression","volume":"83","author":"Willner","year":"1984","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.109949_bib133","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ynstr.2016.08.002","article-title":"The chronic mild stress (CMS) model of depression: history, evaluation and usage","volume":"6","author":"Willner","year":"2017","journal-title":"Neurobiology of Stress"},{"key":"10.1016\/j.neuropharm.2024.109949_bib134","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00213-011-2441-y","article-title":"Pre-treatment with the mGlu2\/3 receptor agonist LY379268 attenuates DOI-induced impulsive responding and regional c-Fos protein expression","volume":"219","author":"Wischhof","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.109949_bib135","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3389\/fnins.2014.00447","article-title":"Monocyte trafficking to the brain with stress and inflammation: a novel axis of immune-to-brain communication that influences mood and behavior","volume":"8","author":"Wohleb","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109949_bib136","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ynstr.2014.11.002","article-title":"Resilience to the effects of social stress: evidence from clinical and preclinical studies on the role of coping strategies","volume":"1","author":"Wood","year":"2015","journal-title":"Neurobiology of Stress"},{"key":"10.1016\/j.neuropharm.2024.109949_bib137","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.biopsych.2014.10.026","article-title":"Inflammatory factors mediate vulnerability to a social stress-induced depressive-like phenotype in passive coping rats","volume":"78","author":"Wood","year":"2015","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.109949_bib139","first-page":"1","article-title":"Counterbalanced microcircuits for Orx1 and Orx2 regulation of stress reactivity","volume":"100059","author":"Yaeger","year":"2020","journal-title":"Medicine in Drug Discovery"},{"key":"10.1016\/j.neuropharm.2024.109949_bib140","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.biopsych.2021.12.019","article-title":"Orexin 1 receptor antagonism in the basolateral amygdala shifts the balance from pro- to antistress signaling and behavior","volume":"91","author":"Yaeger","year":"2022","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.109949_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109168","article-title":"Contextual generalization of social stress learning is modulated by orexin receptors in basolateral amygdala","volume":"215","author":"Yaeger","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.109949_bib142","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.brainres.2014.06.002","article-title":"Unpredictable chronic mild stress induces anxiety and depression-like behaviors and inactivates AMP-activated protein kinase in mice","volume":"1576","author":"Zhu","year":"2014","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2024.109949_bib143","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1023\/A:1024746316245","article-title":"Chronicity in posttraumatic stress disorder (PTSD) and predictors of course of comorbid PTSD in patients with anxiety disorders","volume":"12","author":"Zlotnick","year":"1999","journal-title":"J. Trauma Stress"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824001187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824001187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T03:51:14Z","timestamp":1714967474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390824001187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":142,"alternative-id":["S0028390824001187"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.109949","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single administration of a psychedelic [(R)-DOI] influences coping strategies to an escapable social stress","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.109949","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109949"}}